2nd Positive Interim Trial Data Readout announced in R/R mCRC in Ph 1b/2a IMX-110 IMMINENT-01 Trial
“We are encouraged that in these early cohorts of patients receiving just a fraction of what we believe will be the optimal dose, we continue to see signals of activity of IMX-110 in relapsed/refractory metastatic colorectal cancer patients that received a median of 8 lines of anti-cancer therapies that failed to halt cancer growth prior to receiving IMX-110 + tislelizumab,” said Ilya Rachman, MD PhD, Chief Executive Officer of Immix Biopharma. “In the subsequent higher dose cohorts of IMMINENT-01, we are hopeful that clinical results will further improve. The optimal dose identified in IMMINENT-01 will be utilized in our upcoming Phase 2 IMMINENT-02 clinical trial.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data